Resokaempferol

Resokaempferol

SCHEMBL344710

O=c1c(O)c(-c2ccc(O)cc2)oc2cc(O)ccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 11/20 1.00
KMT2A Q03164 11/20 1.00
CYP3A4 P08684 11/20 1.00
HSD17B10 Q99714 9/20 1.00
KDM4E B2RXH2 9/20 1.00
MAPT P10636 8/20 1.00
ALDH1A1 P00352 8/20 1.00
HPGD P15428 7/20 1.00
CYP2C9 P11712 6/20 1.00
TP53 P04637 6/20 1.00
CASP1 P29466 5/20 1.00
CASP7 P55210 5/20 1.00
MAPK1 P28482 5/20 1.00
CYP2C19 P33261 4/20 1.00
CYP2D6 P10635 3/20 1.00
ALOX15 P16050 6/20 0.82
LMNA P02545 4/20 0.78
CDK5 Q00535 3/20 0.78
CDK5R1 Q15078 3/20 0.78
FTO Q9C0B1 3/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Resokaempferol SCHEMBL30873045 1.00 MEN1 (1.00) MEN1KMT2ACYP3A4HSD17B10KDM4E
SCHEMBL24474226 0.91 MEN1 (0.83) MEN1KMT2ACYP3A4HSD17B10KDM4E
SCHEMBL24474345 0.91 MEN1 (0.83) MEN1KMT2ACYP3A4HSD17B10KDM4E
SCHEMBL24474091 0.91 MEN1 (0.83) MEN1KMT2ACYP3A4HSD17B10KDM4E
SCHEMBL13248718 0.91 MEN1 (0.83) MEN1KMT2ACYP3A4HSD17B10KDM4E
3,7-Dihydroxyflavone SCHEMBL2396684 0.90 CYP3A4 (1.00) MEN1KMT2ACYP3A4HSD17B10KDM4E
3,7-Dihydroxyflavone SCHEMBL29625323 0.90 CYP3A4 (1.00) MEN1KMT2ACYP3A4HSD17B10KDM4E
Fisetin SCHEMBL116861 0.88 MEN1 (1.00) MEN1KMT2ACYP3A4HSD17B10KDM4E
Fisetin SCHEMBL29381611 0.88 MEN1 (1.00) MEN1KMT2ACYP3A4HSD17B10KDM4E
Fisetin SCHEMBL29349742 0.88 MEN1 (1.00) MEN1KMT2ACYP3A4HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230119060-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE MEDIENCE CO., LTD. (KR) 2023-04-20 US claimed
WO-2016071505-A1 MICROBIAL PRODUCTION OF THE FLAVONOIDS GARBANZOL, RESOKAEMPFEROL AND FISETIN DANMARKS TEKNISKE UNIVERSITET (DK) 2016-05-12 WO claimed
US-9155792-B2 RecA inhibitors with antibiotic activity, compositions and methods of use TRUSTEES OF BOSTON UNIVERSITY (US) 2015-10-13 US claimed
US-7897637-B2 Methods of using flavonoids to enhance memory THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2011-03-01 US claimed
US-20100029597-A1 RECA INHIBITORS WITH ANTIBIOTIC ACTIVITY, COMPOSITIONS AND METHODS OF USE TRUSTEES OF BOSTON UNIVERSITY (US) 2010-02-04 US claimed
US-20090264342-A1 COMPOSITIONS AND METHODS FOR ANTIBIOTIC POTENTIATION AND DRUG DISCOVERY TRUSTEES OF BOSTON UNIVERSITY (US) 2009-10-22 US claimed
EP-2028936-A2 COMPOSITIONS AND METHODS FOR ANTIBIOTIC POTENTIATION AND DRUG DISCOVERS TRUSTEES OF BOSTON UNIVERSITY (US) 2009-03-04 EP claimed
WO-2008011538-A2 METHODS OF USING FLAVONOIDS TO ENHANCE MEMORY THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2008-01-24 WO claimed
US-20080021096-A1 METHODS OF USING FLAVONOIDS TO ENHANCE MEMORY THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 2008-01-24 US claimed
WO-2007097940-A2 RECA INHIBITORS WITH ANTIBIOTIC ACTIVITY, COMPOSITIONS AND METHODS OF USE TRUSTEES OF BOSTON UNIVERSITY (US) 2007-08-30 WO claimed
WO-2007095187-A2 COMPOSITIONS AND METHODS FOR ANTIBIOTIC POTENTIATION AND DRUG DISCOVERY TRUSTEES OF BOSTON UNIVERSITY (US) 2007-08-23 WO claimed
US-6872771-B1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2005-03-29 US claimed
JP-2003504327-A 2003-02-04 JP claimed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP claimed
WO-2001080855-A1 TELOMERASE INHIBITORS AND METHODS OF THEIR USE GERON CORPORATION (US) 2001-11-01 WO claimed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO claimed
US-12507703-B2 Methods, devices and compositions for preserving human milk THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2025-12-30 US disclosed
US-20250263774-A1 DISCOVERING NEW XENOBIOTIC SUBSTRATES OF AN UDP-GLYCOSYLTRANSFERASE WITH A HIGH-THROUGHPUT METHOD UNIV NORTH TEXAS (US) 2025-08-21 US disclosed
WO-2001080855-A1 TELOMERASE INHIBITORS AND METHODS OF THEIR USE GERON CORPORATION (US) 2001-11-01 WO disclosed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12507703-B2 Methods, devices and compositions for preserving human milk LPL, CEL, LPO MEN1 4581/4885KMT2A 3264/4885CYP3A4 1678/4885
US-20080021096-A1 METHODS OF USING FLAVONOIDS TO ENHANCE MEMORY FOS, CREBBP, CREB1 MEN1 3520/4885KMT2A 1152/4885CYP3A4 4468/4885
US-20090264342-A1 COMPOSITIONS AND METHODS FOR ANTIBIOTIC POTENTIATION AND DRUG DISCOVERY ATF1, ATF4, STING1 MEN1 4138/4885KMT2A 3617/4885CYP3A4 3260/4885
US-20100029597-A1 RECA INHIBITORS WITH ANTIBIOTIC ACTIVITY, COMPOSITIONS AND METHODS OF USE XPA, WRN, BLM MEN1 2080/4885KMT2A 3866/4885CYP3A4 3512/4885
US-20230119060-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE SLC5A2, SLC5A1, SLC5A6 MEN1 617/4885KMT2A 1807/4885CYP3A4 700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.